ConductScience.org, home

Paper7340879

Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man.

Boobis AR and 6 others. Br J Clin Pharmacol, 1981. Cited by 83 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man. Papers, record 7340879. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7340879

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man.
PubMed
Journal
Br J Clin Pharmacol
PubMed
Year
1981
PubMed
Publication types
Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
83
iCite
Relative citation ratio, by iCite
4.83
iCite
Revised in PubMed
2019-05-12
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Boobis ARA R
2Brodie MJM J
3Kahn GCG C
4Toverud ELE L
5Blair IAI A
6Murray SS
7Davies DSD S

Source PubMed

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AntipyrineMajor topic
Adult
Aged
Female
Half-Life
Humans
Hydroxylation
Kinetics
Liver
Male
Microsomes, Liver
Middle Aged
Oxidation-Reduction

Source PubMed

References22

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
15,690,279Genetic control of drug levels in man: antipyrine.Science1968https://conductscience.org/library/papers/5690279PubMed
26,766,729Monooxygenase activity of human liver in microsomal fractions of needle biopsy specimens.Br J Clin Pharmacol1980https://conductscience.org/library/papers/6766729PubMed
34,146,319Rapid gas-liquid chromatographic estimation of antipyrine in plasma.J Pharm Pharmacol1973https://conductscience.org/library/papers/4146319PubMed
47,362,740Antipyrine as an in vitro probe of mixed function oxidase activity [proceeding].Br J Clin Pharmacol1980https://conductscience.org/library/papers/7362740PubMed
56,105,054Correlations between cytochrome P-450 and oxidative metabolism of benzo[a]pyrene and 7-ethoxycoumarin in human liver in vitro and antipyrine elimination in vivo.Drug Metab Dispos1980https://conductscience.org/library/papers/6105054PubMed
6399,809Multiplicity of mammalian microsomal cytochromes P-45.Pharmacol Rev1979https://conductscience.org/library/papers/399809PubMed
77,448,333An improved combined gas chromatographic mass spectrometric assay for the estimation of norphenazone in urine.Biomed Mass Spectrom1980https://conductscience.org/library/papers/7448333PubMed
94,356,419The metabolism of (ureyl-14C)tolbutamide in vitro and in vivo in man.Life Sci1973https://conductscience.org/library/papers/4356419PubMed
104,813,341Correlation of the plasma elimination of antipyrine and the appearance of 4-hydroxy antipyrine in the urine of man.Biochem Pharmacol1974https://conductscience.org/library/papers/4813341PubMed
114,593,769The effect of spironolactone on antipyrine metabolism in man.Pharmacology1973https://conductscience.org/library/papers/4593769PubMed
124,418,208Metabolism of antipyrine by the epoxide-diol pathway in the rat, guinea pig and human.Res Commun Chem Pathol Pharmacol1974https://conductscience.org/library/papers/4418208PubMed
134,611,464Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administration.Clin Pharmacol Ther1974https://conductscience.org/library/papers/4611464PubMed
14849,678Influence of rifampicin on drug metabolism: differences between hexobarbital and antipyrine.Clin Pharmacol Ther1977https://conductscience.org/library/papers/849678PubMed
15732,536Antipyrine metabolism in man.Life Sci1978https://conductscience.org/library/papers/732536PubMed
16433,309Comparison of rate of hepatic metabolism in vitro and half-life for antipyrine in vivo in three species.Xenobiotica1979https://conductscience.org/library/papers/433309PubMed
17461,498Assay of antipyrine and its primary metabolites in plasma, saliva and urine by high-performance liquid chromatography and some preliminary results in man.Pharmacology1979https://conductscience.org/library/papers/461498PubMed
18111,889The antipyrine test in clinical pharmacology: conceptions and misconceptions.Clin Pharmacol Ther1979https://conductscience.org/library/papers/111889PubMed
19487,696Drug metabolism in liver disease: activity of hepatic microsomal metabolizing enzymes.Clin Pharmacol Ther1979https://conductscience.org/library/papers/487696PubMed
20533,575Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers.Br J Clin Pharmacol1979https://conductscience.org/library/papers/533575PubMed
21522,9064,4'-Dihydroxyphenazone as an urinary metabolite of phenazone in different species including man.Naunyn Schmiedebergs Arch Pharmacol1979https://conductscience.org/library/papers/522906PubMed

See all 22 references

Cited by29

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 83 citations.

PMIDTitleJournalYearIn PapersSource
10,412,897Effect of tacrine hydrochloride on hepatic drug metabolism.Eur J Drug Metab Pharmacokinet1999https://conductscience.org/library/papers/10412897PubMed
8,403,737The relationship between phenazone (antipyrine) metabolite formation and theophylline metabolism in healthy and frail elderly women.Clin Pharmacokinet1993https://conductscience.org/library/papers/8403737PubMed
7,621,853The acetylation phenotype: does it contribute to the non-linearity of the metabolite pharmacokinetics of metamizol?Eur J Clin Pharmacol1995https://conductscience.org/library/papers/7621853PubMed
7,082,530Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver.Br J Clin Pharmacol1982https://conductscience.org/library/papers/7082530PubMed
6,849,767Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine.Br J Clin Pharmacol1983https://conductscience.org/library/papers/6849767PubMed
6,697,063Tolbutamide as a model drug for the study of enzyme induction and enzyme inhibition in the rat.Br J Pharmacol1984https://conductscience.org/library/papers/6697063PubMed
6,639,836Effect of chloroquine and primaquine on antipyrine metabolism.Br J Clin Pharmacol1983https://conductscience.org/library/papers/6639836PubMed
6,627,809Interindividual variations in drug disposition. Clinical implications and methods of investigation.Clin Pharmacokinet1983https://conductscience.org/library/papers/6627809PubMed
6,510,457Antipyrine clearance in patients with Gilbert's syndrome.Eur J Clin Pharmacol1984https://conductscience.org/library/papers/6510457PubMed
6,508,979Influence of rifampicin treatment on antipyrine clearance and metabolite formation in patients with tuberculosis.Br J Clin Pharmacol1984https://conductscience.org/library/papers/6508979PubMed
6,487,479Effects of cimetidine on carbamazepine auto- and hetero-induction in man.Br J Clin Pharmacol1984https://conductscience.org/library/papers/6487479PubMed
6,142,865Noninvasive assessment of microsomal enzyme activity in occupational medicine: present state of knowledge and future perspectives.Int Arch Occup Environ Health1984https://conductscience.org/library/papers/6142865PubMed
6,128,018Assessment of the drug metabolism capacity of the liver.Br J Clin Pharmacol1982https://conductscience.org/library/papers/6128018PubMed
4,027,138Phenacetin O-deethylase: an activity of a cytochrome P-450 showing genetic linkage with that catalysing the 4-hydroxylation of debrisoquine?Br J Clin Pharmacol1985https://conductscience.org/library/papers/4027138PubMed
3,994,897Oral morphine in cancer patients: in vivo kinetics and in vitro hepatic glucuronidation.Br J Clin Pharmacol1985https://conductscience.org/library/papers/3994897PubMed
3,620,285The disposition of antipyrine and its metabolites in young and elderly healthy volunteers.Br J Clin Pharmacol1987https://conductscience.org/library/papers/3620285PubMed
3,567,053Antipyrine metabolism in acute hepatic porphyria in relapse and remission.Br J Clin Pharmacol1987https://conductscience.org/library/papers/3567053PubMed
3,440,100Disposition of antipyrine in African patients with Hodgkin's lymphoma.Br J Clin Pharmacol1987https://conductscience.org/library/papers/3440100PubMed
3,402,522Differential effect of type I and type II diabetes on antipyrine disposition in man.Eur J Clin Pharmacol1988https://conductscience.org/library/papers/3402522PubMed
3,383,988Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide.Eur J Clin Pharmacol1988https://conductscience.org/library/papers/3383988PubMed

See all 29 cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/7340879

GET https://conductscience.org/api/papers/v1/7340879/references?page=2